## CLAIMS

We claim:

1. A compound of Formula I



Formula I

wherein

R is selected from the group consisting of OH, $N_3$, -$OR_1$, -O-aryl, -O-heteroaryl, -$OSO_2R_2$, -$NR_3R_4$, and



wherein

(i) $R_1$ is benzyl or $C_{2-6}$-acyl;

(ii) $R_2$ is selected from the group consisting of phenyl, tolyl, and $C_{1-8}$-alkyl; and

(iii) $R_3$ and $R_4$ are independently selected from the group consisting of hydrogen, $C_{3-6}$-cycloalkyl, phenyl, tert-butoxycarbonyl, fluorenyloxycarbonyl, benzyloxycarbonyl, -$CO_2$-$R_5$, -CO-$R_5$, -CO-$SR_5$, -CS-$R_5$, P(O)($OR_6$)($OR_7$), -$SO_2$-$R_8$ and $C_{1-6}$-alkyl optionally substituted with 1 to 3 members independently selected from the group consisting of $C_{1-5}$-alkoxycarbonyl, OH, cyano, and halogen, wherein

$R_5$ is selected from the group consisting of hydrogen, $C_{3-6}$-cycloalkyl, trifluoromethyl, phenyl, benzyl, and $C_{1-6}$-alkyl optionally substituted with 1 to 3 members independently selected from the group consisting of $C_{1-5}$-alkoxycarbonyl, OH, cyano, halogen, and –$NR_9R_{10}$ in which $R_9$ and $R_{10}$ are independently selected from the group consisting of hydrogen, phenyl and $C_{1-4}$-alkyl;

$R_6$ and $R_7$ are independently hydrogen or $C_{1-4}$-alkyl; and

$R_8$ is phenyl or $C_{1-4}$-alkyl;

$R_{11}$ is selected from the group consisting of hydrogen, alkyl, $-OR_{13}$, $-SR_{13}$, amino, $-NR_{13}R_{14}$, aryl($C_{1-8}$)alkyl, and mono-, di-, tri-, or per-halo $C_{1-8}$-alkyl;

$R_{12}$ is selected from the group consisting of CN, $-COR_{13}$, $-COOR_{13}$, $-CO-NR_{13}R_{14}$, $-SO_2R_{13}$, $-SO_2-NR_{13}R_{14}$, and nitro; and

$R_{13}$ and $R_{14}$ are independently selected from the group consisting of hydrogen, alkyl, and aryl, or $R_{13}$ and $R_{14}$ taken together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group;

X is 0 to 4 members independently selected from the group consisting of halogen, OH, mercapto, nitro, halo-$C_{1-8}$-alkyl, $C_{1-8}$-alkoxy, $C_{1-8}$-alkylthio, $C_{1-8}$-alkyl-amino, di($C_{1-8}$-alkyl)amino, formyl, carboxy, alkoxycarbonyl, $C_{1-8}$ alkyl-CO-O-, $C_{1-8}$ alkyl-CO-NH-, carboxamide, aryl, heteroaryl, CN, amino, $C_{3-6}$-cycloalkyl, $C_{1-8}$-alkyl optionally substituted with one or more members selected from the group consisting of F, Cl, OH, $C_{1-8}$ alkoxy and $C_{1-8}$ acyloxy; and

Y is a radical of Formula II:




Formula II

wherein

$R_{15}$, $R_{16}$, $R_{17}$, $R_{18}$, $R_{19}$, and $R_{20}$ are each independently selected from the group consisting of hydrogen, CN, nitro, $C_{1-8}$-alkyl, halo-$C_{1-8}$-alkyl, formyl, carboxy,

alkoxycarbonyl, carboxamide, aryl, and heteroaryl, or $R_{15}$ and $R_{16}$ and/or $R_{17}$ and $R_{18}$ and/or $R_{19}$ and $R_{20}$ together form an oxo group;

the moiety W represents any five- to ten-membered aromatic or heteroaromatic ring, said heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N;

Z is selected from the group consisting of hydrogen, halogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, CN, CHO, alkyl-CO-, alkoxy, ($C_{1-8}$-alkyl)-CONH-, and $R_{21}R_{22}$N-alkyl- wherein $R_{21}$ and $R_{22}$ are independently selected from the group consisting of hydrogen, $C_{1-6}$-alkyl, benzyl, aryl, and heteroaryl, or $R_{21}$and $R_{22}$ together with the nitrogen to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group; and

m is 0 or 1

and the pharmaceutically acceptable salts and esters thereof.

2. The compound of claim 1 wherein X is halogen.

3. The compound of claim 1 wherein Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

4. The compound of claim 1 wherein the moiety W is a fused phenyl ring or a five- or six-membered heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N.

5. The compound of claim 1 wherein Y is selected from the group consisting of



wherein

Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, alkyl-CO-, and $R_{21}R_{22}N$-alkyl- wherein $R_{21}$ and $R_{22}$ are independently selected from the group consisting of hydrogen, $C_{1-6}$-alkyl, benzyl, aryl, and heteroaryl, or $R_{21}$and $R_{22}$ together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group.

6. The compound of claim 5 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

7. The compound of claim 1 wherein R is selected from the group consisting of



8. The compound of claim 6 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

9. A compound of Claim 1 having the formula:



10. A compound of Claim 1 having the formula:



11. A compound of Claim 1 having the formula:



12. A compound of Claim 1 having the formula:



13. A compound of Claim 1 having the formula:



14. A compound of Claim 1 having the formula:



15. A compound of Claim 1 having the formula:



16. A compound of Claim 1 having the formula:



17. A compound of Claim 1 having the formula:



18. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

19. A method of treating a subject having a condition caused by or contributed to by bacterial infection, which comprises administering to said mammal a therapeutically effective amount of the compound according to Claim 1.

20. A method of preventing a subject from suffering from a condition caused by or contributed to by bacterial infection, which comprises administering to the subject a prophylactically effective dose of the pharmaceutical composition of a compound according to Claim 1.

21. The method of Claim 19 or 20 wherein said condition is selected from the group consisting of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, bone and joint infections and hospital-acquired lung infections.

22. The method of Claim 19 or 20 wherein said bacterium is selected from the group consisting of *S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes, Enterococcus spp., Moraxella catarrhalis* and *H. influenzae*.

23. The method of Claim 19 or 20 wherein said bacterium is a Gram-positive coccus.

24. The method of Claim 23 wherein said Gram-positive coccus is drug-resistant.